Compare MPLX LP (MPLX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Spyre Therapeutics Inc. Common Stock — how do they compare? MPLX LP trades at $57.5 (market cap $58.26B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: MPLX LP is far larger — about 7.9× Spyre Therapeutics Inc. Common Stock's market cap, and MPLX LP pays a 7.49% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| MPLX | SYRE | |
|---|---|---|
Market Cap | $58.26B | $7.35B |
Volume | 2,089,896 | 1,624,631 |
Sector | Energy | Health |
52-Week High | $60.51 | $108.92 |
52-Week Low | $48.53 | $22.18 |
Enterprise Value | $83.36B | $6.35B |
Dividend Yield | 7.49% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.91, up 0.14% with a bearish technical signal despite strong fundamentals. The company reported $11.47B revenue and $4.91B net income for 2025, with robust profitability margins (40.45% net margin, 33.95% ROE). Recent earnings show mixed results with Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 12% upside potential.
The investment case balances strong cash flow generation and dividend yield against energy market volatility risks. MPLX's fee-based midstream model provides revenue stability, but recent technical weakness and earnings misses warrant caution. The stock offers value with a 12.24 P/E ratio and dividend income potential, though investors should monitor Q3 2026 earnings due November 3rd for confirmation of business momentum.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
